Merck revs up dealmaking engine ahead of #JPM22, inking collaborations with AI protein design player Absci

Max Gelman

Senior Editor

In the year-plus since Roger Perlmutter left his post leading Merck’s R&D efforts, the Big Pharma’s new leadership has continued to pursue an aggressive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck revs up dealmaking engine ahead of #JPM22, inking collaborations with AI protein design player Absci

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA lifts hold on Entrada's Duchenne drug after two years

How AI can address ongoing challenges in the life sciences industry

Mer­ck revs up deal­mak­ing en­gine ahead of #JPM22, ink­ing col­lab­o­ra­tions with AI pro­tein de­sign play­er Ab­sci

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Merck revs up dealmaking engine ahead of #JPM22, inking collaborations with AI protein design player Absci